Of the 37 human orthologous SHs identified, four are used as biomarkers, i.e., FASN for the diagnosis of breast cancer, PLA2G7 for the diagnosis of ischaemic stroke and coronary artery disease, LCAT for the treatment efficacy of dyslipidaemia and CELA1 for the treatment efficacy of pancreatic cancer. This evidence concerns the gene PLA2G7 and ischemic stroke.